1. Home
  2. QNTM
  3. QNTM News

Latest QUANTUM BIOPHARMA LTD (QNTM) News on April 2, 2025

Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis
QNTM

GlobeNewswire

2 days ago

Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis

Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms
QNTM

GlobeNewswire

2 days ago

Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms

QNTM

Newsfile

3 days ago

Quantum BioPharma Provides Corporate Update

QNTM

ACCESS Newswire

5 days ago

Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern

Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors
QNTM

GlobeNewswire

6 days ago

Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors

Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail Sales
QNTM

GlobeNewswire

7 days ago

Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail Sales

QNTM

Newsfile

16 days ago

Quantum BioPharma Unaware of Any Material Change

Quantum BioPharma Provides Corporate Update
QNTM

Newsfile

a month ago

Quantum BioPharma Provides Corporate Update

Psychedelic: GH Research, Compass Pathways report earnings results
QNTM

TipRanks

a month ago

Psychedelic: GH Research, Compass Pathways report earnings results

Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
QNTM

GlobeNewswire

a month ago

Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302

Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
QNTM

GlobeNewswire

2 months ago

Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program

Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs
QNTM

GlobeNewswire

2 months ago

Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs

Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study
QNTM

GlobeNewswire

2 months ago

Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study

Quantum to Release Fiscal Third Quarter 2025 Financial Results on Wednesday, February 12, 2025
QNTM

Business Wire

2 months ago

Quantum to Release Fiscal Third Quarter 2025 Financial Results on Wednesday, February 12, 2025

Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial
QNTM

GlobeNewswire

2 months ago

Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial

QNTM

ACCESS Newswire

3 months ago

Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates

QNTM

ACCESS Newswire

3 months ago

Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM

QNTM

ACCESSWIRE

3 months ago

Quantum Biopharma Ltd. Approved to Dual List on Upstream

QNTM

ACCESSWIRE

3 months ago

Quantum Biopharma Announces Closing of Second Tranche

QNTM

ACCESSWIRE

3 months ago

Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency

QNTM

ACCESSWIRE

4 months ago

Quantum Biopharma Announces Closing of First Tranche

QNTM

ACCESSWIRE

4 months ago

Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)

QNTM

ACCESSWIRE

4 months ago

Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million

QNTM

ACCESSWIRE

4 months ago

Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation

Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia
QNTM

ACCESSWIRE

5 months ago

Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia

QNTM

ACCESSWIRE

5 months ago

Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
QNTM

Newsfile

5 months ago

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
QNTM

ACCESSWIRE

5 months ago

Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America
QNTM

Newsfile

6 months ago

Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America

Quantum Biopharma Provides Corporate Update
QNTM

ACCESSWIRE

6 months ago

Quantum Biopharma Provides Corporate Update

Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US
QNTM

ACCESSWIRE

6 months ago

Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US

Quantum BioPharma Closes Private Placement Offering
QNTM

Newsfile

7 months ago

Quantum BioPharma Closes Private Placement Offering

Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
QNTM

ACCESSWIRE

7 months ago

Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis

QNTM

ACCESSWIRE

7 months ago

Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements

Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80
QNTM

ACCESSWIRE

7 months ago

Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80

QNTM

ACCESSWIRE

7 months ago

Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can "own NOW and what’s NEXT"

QNTM

ACCESSWIRE

7 months ago

Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update

QNTM

Newsfile

8 months ago

FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol "QNTM"

Share on Social Networks: